Experimental and Clinical Preliminary Study of Immunomodulators in the Treatment of Ocular Herpes

Denis, Jean‐Noël; Hoang–Xuan, T.; Bonissent, J. F.; Dogbe, K.; Clay, Candice C.; Viza, D.; Rosenfeld, Fritz; Phillips, John C.; Vich, J.M.

doi:10.1007/978-94-009-5518-9_16

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, encouraging results were reported by Abramson et aI. [I] in treating uveitis patients with transfer factor, whereas in a limited number of RHK patients, we have confirmed that HSV-specific TF reduces the number of relapses and also significantly decreases the HSV-l-caused opacities in rabbits' eyes [5,20]. These observations made the present clinical study so much more plausible.…”

Section: Introductionsupporting

confidence: 76%

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Pizza

Meduri

et al. 1994

Biotherapy

View full text Add to dashboard Cite

Transfer Factor is a dialysable moiety obtained from immune lymphocytes. It has been successfully used for the treatment of several viral infections including labial and genital herpes. In the present study, thirty-three patients with low immune response to HSV antigens and suffering from herpes ocular infections were orally treated with HSV-specific transfer factor (TF). Their relapse index was reduced from 20.1 before treatment to 0.51 after TF administration, with only 6/33 patients relapsing. Although this is not a placebo-controlled-randomized study, the results suggest that TF specific for HSV antigens may be efficacious for preventing relapses of ocular herpes infections as has been the case with genital and labial localisations.

show abstract

Section: Introductionsupporting

confidence: 76%

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Pizza

Meduri

et al. 1994

Biotherapy

View full text Add to dashboard Cite

show abstract

“…Both treatments showed a beneficial effect, TF seemingly being more efficacious in diminishing their frequency. 35 These results contrasted with those reported by Smolin et al 36 who failed to prevent or improve experimental guinea pig herpes or Candida albicans induced keratitis by using TF from blood donors, thus illustrating that antigen specificity and potency of the TF preparations is of the essence.…”

contrasting

confidence: 57%

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Levine

Pizza²,

Ajmera³

et al. 2011

Advances in Tumor Virology

View full text Add to dashboard Cite

Abstract:Transfer factor (TF) is a lymphocyte extract of low molecular weight capable of transferring antigen-specific information to T-lymphocytes. A number of reports have documented its efficacy in the control of acute viral infections, particularly those associated with herpes viruses. There have been also several reports of clinical trials utilizing Epstein-Barr Virus-specific TF in associated malignancies, particularly Burkitt's lymphoma and nasopharyngeal carcinoma. One of the more important advances in the field has been the ability to produce standardized TF in tissue culture or by animal immunization, allowing the opportunity to develop well-controlled clinical trials, and the possibility to replicate them in independent studies. This review discusses the studies that have provided the best information regarding the efficacy of TF in fighting viral infections and suggests areas where clinical trials could be most useful, such as the prevention of human papilloma virus induced cervical cancer and human T-cell lymphotropic virus induced adult T-cell leukemia/ lymphoma.

show abstract

Efficacy of transfer factor in treating patients with recurrent ocular herpes infections

et al. 1996

View full text Add to dashboard Cite

Recurrent ocular herpes is an insoluble problem for the clinician. As cellular immunity plays an important role in controlling herpes relapses, and other studies have shown the efficacy of HSV-specific transfer factor (TF) for the treatment of herpes patients, an open clinical trial was undertaken in 134 patients (71 keratitis, 29 kerato-uveitis, 34 uveitis) suffering from recurrent ocular herpetic infections. The mean duration of the treatment was 358 days, and the entire follow-up period 189,121 before, and 64,062 days after TF treatment. The cell-mediated immune response to the viral antigens, evaluated by the lymphocyte stimulation test (LST) and the leucocyte migration test (LMT) (P < 0.001), was significantly increased by the TF treatment. The total number of relapses was decreased significantly during/after TF treatment, dropping from 832 before, to 89 after treatment, whereas the cumulative relapse index (RI) dropped, during the same period, from 13.2 to 4.17 (P < 0.0001). No side effects were observed. It is concluded that patients with relapsing ocular herpes can benefit from treatment with HSV-specific TF.

show abstract

Experimental and Clinical Preliminary Study of Immunomodulators in the Treatment of Ocular Herpes

Cited by 3 publications

References 1 publication

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Transfer factor prevents relapses in herpes keratitis patients: A pilot study

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Efficacy of transfer factor in treating patients with recurrent ocular herpes infections

Contact Info

Product

Resources

About